Quarterly report pursuant to Section 13 or 15(d)

Note 17 - Subsequent Events

v3.8.0.1
Note 17 - Subsequent Events
3 Months Ended
Mar. 31, 2018
Notes to Financial Statements  
Subsequent Events [Text Block]
1
7
.
Subsequent Events
 
The Company has evaluated events and transactions subsequent to
March 31, 2018
and through the date these consolidated financial statements were included in this Form
10
-Q and filed with the SEC.
 
 
a.
Amendment to Asset Purchase Agreement:
On
April 2, 2018,
the Company entered into an Amendment to the Asset Purchase Agreement. Pursuant to the Amendment, Cardinal Health
414
paid the Company approximately
$6.0
million and agreed to pay the Company an amount equal to the unused portion of the letter of credit (
not
to exceed approximately
$7.1
 million) promptly after the earlier of (i) the expiration of the letter of credit and (ii) the receipt by Cardinal Health
414
of evidence of the return and cancellation of the letter of credit. In exchange, the obligation of Cardinal Health
414
to make any further contingent payments has been eliminated. Cardinal Health
414
is still obligated to make the milestone payments in accordance with the terms of the earnout provisions of the Purchase Agreement.
 
 
b.
CRG Litigation:
On
January 16, 2018,
the Company filed an emergency motion to set supersedeas bond and to modify judgment, describing the double recovery created by the
$66.0
million award without taking into account the
$4.1
million payment in
June 2016,
requesting that the judgment be modified to set the supersedeas amount at
$2.9
million so that the Company could stay enforcement of the judgment pending appeal. The Texas Court refused to rule on this motion, and the court of appeals entered an order compelling the Texas Court to set a supersedeas amount. On
March 26, 2018,
the Texas Court ordered the Company to put up a supersedeas bond in the amount of
$7.7
 million. The Company filed for an emergency stay of the order in the appellate court in Harris County. On
April 2, 2018,
the appellate court denied the Company’s emergency stay motion. The Company continues to believe that the
$4.1
million paid to CRG in
June 2016
should be credited as payment toward the
$66.0
million total, and the Company intends to further contest the matter through the appellate court in Texas.
 
On
April 9, 2018,
CRG drew approximately
$7.1
million on the letter of credit. This was in addition to the
$4.1
million and the
$59.0
million that Navidea had previously paid to CRG.
 
On
April 12, 2018
Navidea filed suit in the Ohio Court against the Lenders.  The suit asserts that the Lenders fraudulently induced Navidea to enter into a settlement agreement and breached the terms of the same through certain actions taken by the Lenders in connection with the Global Settlement Agreement reached in
2017,
pursuant to which Navidea agreed to pay up to
$66.0
million to Lenders, as well as through actions and misrepresentations by CRG after the Global Settlement Agreement was executed.  The suit also asserts claims for conversion and unjust enrichment against the Lenders for their collection of more than
$66.0
million, the maximum permitted under the Global Settlement Agreement, and their double recovery of amounts paid as part of the
$4.1
million paid in
June 2016
and recovered again as part of the
$66.0
million. CRG’s double recovery and recovery of more than
$66.0
million are due to CRG drawing the entire
$7.1
million on the Cardinal Health
414
letter of credit. To date,
no
answer or other response or motion has been filed by the Lenders to Navidea’s complaint.
 
In a related proceeding before the Ohio Court, initially filed in
2016,
and under which the Global Settlement Agreement was reached in
2017,
the Ohio Court has issued preliminary findings that the settlement gave rise to a
$66.0
million cap on amounts owed to Lenders by Navidea and that Navidea might
not
have been properly credited for certain funds in excess of
$4.1
million previously swept by Lenders from a bank account owned by Navidea.  The Ohio Court also made a preliminary ruling that it possessed jurisdiction to interpret the settlement agreement at issue. The Company intends to pursue recovery of the
$4.1
million, and other damages, in the Ohio Court.
 
On
April 11, 2018,
CRG filed a new suit against the Company in the Texas Court. This new suit seeks a declaratory judgment that CRG did
not
breach the Global Settlement Agreement by drawing approximately
$7.1
million on the Cardinal Health
414
letter of credit. On
April 16, 2018,
CRG moved the Texas Court to issue an anti-suit injunction barring the Company from litigating in the Ohio Court. The Texas Court denied that motion on
April 27, 2018.
CRG served the Company with the new Texas suit on
May 2, 2018,
and the Company’s answer is due on
May 21, 2018.
The Company intends to contest this issue in the Ohio Court, the Texas Court, and on appeal in Texas.
 
 
c.
Platinum Litigation:
A settlement conference was held on
April 30, 2018
and attended by a representative of Navidea and counsel, Dr. Goldberg and counsel, and counsel for PPVA and PPCO.  PPCO requested participation in the conference due to certain recent issues that have arisen concerning potential liability of PPCO to Navidea under the release and indemnification provisions of the payoff letter issued by PPCO in connection with the payment PPCO has received under the Platinum Loan Agreement.  The settlement conference resulted in
no
agreement. Because the funds sought by Platinum-Montaur are subject to claims of competing ownership, the Company intends to continue to defend itself in the action.